• 1
    Gurney JG, Swenson AR, Bulterys M. Malignant bone tumors. In: RiesLAG, SmithMA, GurneyJG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program; 1999: 99-110.
  • 2
    Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am. 1997; 44: 973-989.
  • 3
    Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422-441.
  • 4
    Meyers P, Schwartz C, Krailo M, et al. Osteosarcoma: a randomized, prospective study of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23: 2004-2011.
  • 5
    Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremity or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20: 776-790.
  • 6
    Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastastic osteosarcoma of the extremity with pre- and postoperative chemotherapy, CCG-782: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 76-84.
  • 7
    Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993; 72: 3227-3238.
  • 8
    Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement Arch Pathol Lab Med. 1977; 101: 14-18.
  • 9
    Salzer-Kuntschik M, Delling G, Beron G, et al. Morphological grades of regression in osteosarcoma. J Cancer Res Clin Oncol. 1983; 106: 21-24.
  • 10
    Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994; 12: 423-431.
  • 11
    Picci P, Sangiorgi L, Rougraff BT, et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994; 12: 2699-2705.
  • 12
    Murphy WA. Imaging bone tumors in the 1990s. Cancer. 1991; 67: 1169-1176.
  • 13
    Hawkins DS, Rajendran JG, Conrad EU, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18] fluoro-deoxyglucose positron emission tomography. Cancer. 2002; 94: 3277-3284.
  • 14
    Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005; 103: 339-348.
  • 15
    Hawkins DS, Schuetze SM, Butrynski JE, et al. [F-18]-fluorodeoxy-D-glucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005; 23: 8828-8834.
  • 16
    Zalupski MM, Rankin C, Ryan JR, et al. Adjuvant therapy of osteosarcoma: a phase II trial, Southwest Oncology Group Study 9139. Cancer. 2004; 100: 818-825.
  • 17
    Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18]-fluorodeoxyglucose positron emission tomography in pretreatment evaluation and grading of sarcoma. Clin Cancer Res. 1998; 4: 1215-1220.
  • 18
    Folpe AL, Lyles RH, Sprouse JT, et al. [F-18]-fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000; 6: 1279-1287.
  • 19
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 20
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I-analysis and examples. Br J Cancer. 1977; 35: 1-39.
  • 21
    Schuetze SM, Griffith KA, Rubin BP, et al. FDG PET but not RECIST agrees with histologic response of soft tissue sarcoma to neoadjuvant chemotherapy. 2005 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol. 2005; 23( 16S; pt I of II June 1 suppl; ). Abstract 9005.
  • 22
    Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med. 2002; 29: 1149-1154.
  • 23
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472-480.
  • 24
    Sankhala KK, Chawla SP, Iagaru A, et al. Early response evaluation of therapy with AP23573 (an mTOR inhibitor) using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan. 2005 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol. 2005; 23( 16S; pt I of II June 2 suppl; ), Abstract 9028.
  • 25
    Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979; 43: 2163-2177.
  • 26
    Meyer PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998; 16: 2452-2458.